207 related articles for article (PubMed ID: 28187206)
1. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.
Domínguez À; Soldevila N; Toledo D; Torner N; Force L; Pérez MJ; Martín V; Rodríguez-Rojas L; Astray J; Egurrola M; Sanz F; Castilla J;
PLoS One; 2017; 12(2):e0171943. PubMed ID: 28187206
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
Heo JY; Seo YB; Choi WS; Kim EJ; Jeong HW; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Song JY
J Infect Dis; 2022 Mar; 225(5):836-845. PubMed ID: 34537847
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
5. Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.
Chiou WY; Hung SK; Lai CL; Lin HY; Su YC; Chen YC; Shen BJ; Chen LC; Tsai SJ; Lee MS; Li CY
Medicine (Baltimore); 2015 Jul; 94(26):e1022. PubMed ID: 26131806
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation.
Demirdogen Cetinoglu E; Uzaslan E; Sayıner A; Cilli A; Kılınc O; Sakar Coskun A; Hazar A; Kokturk N; Filiz A; Polatli M;
Hum Vaccin Immunother; 2017 Sep; 13(9):2072-2077. PubMed ID: 28708954
[TBL] [Abstract][Full Text] [Related]
8. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.
Domínguez A; Castilla J; Godoy P; Delgado-Rodríguez M; Saez M; Soldevila N; Astray J; Mayoral JM; Martín V; Quintana JM; González-Candelas F; Galán JC; Tamames S; Castro A; Baricot M; Garín O; Pumarola T;
Hum Vaccin Immunother; 2013 Apr; 9(4):865-73. PubMed ID: 23563516
[TBL] [Abstract][Full Text] [Related]
10. Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions.
Hyun H; Jang AY; Suh JW; Bae IG; Choi WS; Seo YB; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim MJ; Song JY
J Korean Med Sci; 2023 Oct; 38(42):e330. PubMed ID: 37904655
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study.
Wiemken TL; Carrico RM; Klein SL; Jonsson CB; Peyrani P; Kelley RR; Aliberti S; Blasi F; Fernandez-Gonzalez R; Lopardo G; Ramirez JA;
Vaccine; 2014 Apr; 32(19):2198-203. PubMed ID: 24613522
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.
Domínguez A; Izquierdo C; Salleras L; Ruiz L; Sousa D; Bayas JM; Nebot M; Varona W; Celorrio JM; Carratalà J;
Eur Respir J; 2010 Sep; 36(3):608-14. PubMed ID: 20075048
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
[TBL] [Abstract][Full Text] [Related]
15. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance.
Sgambatti S; Minamisava R; Bierrenbach AL; Toscano CM; Vieira MA; Policena G; Andrade AL
Vaccine; 2016 Jan; 34(5):663-670. PubMed ID: 26706272
[TBL] [Abstract][Full Text] [Related]
16. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina.
López EL; Glatstein E; Ezcurra GC; Iacono M; Teplitz E; Garnero AV; Lazzarini DL; Vázquez M; Contrini MM
J Pediatric Infect Dis Soc; 2018 Feb; 7(1):30-35. PubMed ID: 28339727
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
[TBL] [Abstract][Full Text] [Related]
18. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
Ihara H; Kikuchi K; Taniguchi H; Fujita S; Tsuruta Y; Kato M; Mitsuishi Y; Tajima K; Kodama Y; Takahashi F; Takahashi K; Azuma N
Vaccine; 2019 Oct; 37(43):6447-6453. PubMed ID: 31526624
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
[TBL] [Abstract][Full Text] [Related]
20. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type
Chandler T; Furmanek S; Carrico R; Balcom D; Arnold F; Ramirez J
Microorganisms; 2022 Mar; 10(3):. PubMed ID: 35336135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
